Skip to main content
Erschienen in: Tumor Biology 5/2013

01.10.2013 | Research Article

Lack of association of genetic polymorphisms of angiotensin converting enzyme 1 and angiotensin II type 1 receptor with breast cancer risk in Iranian population

verfasst von: Soha Namazi, Ahmad Monabati, Shirin Ardeshir-Rouhani-Fard, Negar Azarpira

Erschienen in: Tumor Biology | Ausgabe 5/2013

Einloggen, um Zugang zu erhalten

Abstract

We aimed to investigate the association of insertion/deletion (I/D) and A1166C polymorphisms of angiotensin I converting enzyme 1 and angiotensin II type 1 receptor genes, respectively and their combination on breast cancer risk in an Iranian population. A case–control study (70 cases, 70 controls) was performed on an Iranian population. The I/D and A1166C polymorphisms were analyzed by polymerase chain reaction (PCR) and restriction fragment length polymorphism PCR, respectively. The results revealed no significant difference between cases and controls in I/D (p = 0.14) and A1166C (p = 0.94) polymorphisms after adjustment for breast cancer known risk factors. In combined genotype analysis, considering DD and AA genotypes as low-risk genotypes, women with one and two high-risk genotypes (one high-risk genotype: adjusted odds ratio (OR), 1.24; two high-risk genotypes: adjusted OR, 1.97) were at higher risk for breast cancer. Also, the highest risk for breast cancer was seen in a subgroup of postmenopausal women carriers of two high-risk genotypes (adjusted OR, 2.41). In conclusion, I/D and A1166C polymorphisms are not significantly associated with breast cancer risk in the Iranian population; however, the combination of these two polymorphisms seems to have a synergic effect on the risk of breast cancer particularly in postmenopausal women, which may deserve consideration in large-scale case–control studies.
Literatur
1.
Zurück zum Zitat Harirchi I, Kolahdoozan S, Karbakhsh M, Chegini N, Mohseni SM, Montazeri A, et al. Twenty years of breast cancer in Iran: downstaging without a formal screening program. Ann Oncol. 2011;22:93–7.CrossRefPubMed Harirchi I, Kolahdoozan S, Karbakhsh M, Chegini N, Mohseni SM, Montazeri A, et al. Twenty years of breast cancer in Iran: downstaging without a formal screening program. Ann Oncol. 2011;22:93–7.CrossRefPubMed
2.
Zurück zum Zitat Paul M, Mehr AP, Kreutz R. Physiology of local renin–angiotensin systems. Physiol Rev. 2006;86:747–803.CrossRefPubMed Paul M, Mehr AP, Kreutz R. Physiology of local renin–angiotensin systems. Physiol Rev. 2006;86:747–803.CrossRefPubMed
3.
Zurück zum Zitat Ager EI, Neo J, Christophi C. The renin-angiotensin system and malignancy. Carcinogenesis. 2008;29:1675–84.CrossRefPubMed Ager EI, Neo J, Christophi C. The renin-angiotensin system and malignancy. Carcinogenesis. 2008;29:1675–84.CrossRefPubMed
4.
Zurück zum Zitat Rosenthal T, Gavras I. Angiotensin inhibition and malignancies: a review. J Hum Hypertens. 2009;23:623–35.CrossRefPubMed Rosenthal T, Gavras I. Angiotensin inhibition and malignancies: a review. J Hum Hypertens. 2009;23:623–35.CrossRefPubMed
5.
Zurück zum Zitat Sayed-Tabatabaei FA, Oostra BA, Isaacs A, Van Duijn CM, Witteman JCM. ACE polymorphisms. Circ Res. 2006;98:1123–33.CrossRefPubMed Sayed-Tabatabaei FA, Oostra BA, Isaacs A, Van Duijn CM, Witteman JCM. ACE polymorphisms. Circ Res. 2006;98:1123–33.CrossRefPubMed
6.
Zurück zum Zitat Rigat B, Hubert C, Alhenc-Gelas F, Cambien F, Corvol P, Soubrier F. An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels. J Clin Invest. 1990;86:1343–6.PubMedCentralCrossRefPubMed Rigat B, Hubert C, Alhenc-Gelas F, Cambien F, Corvol P, Soubrier F. An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels. J Clin Invest. 1990;86:1343–6.PubMedCentralCrossRefPubMed
7.
Zurück zum Zitat Haiman CA, Henderson SO, Bretsky P, Kolonel LN, Henderson BE. Genetic variation in angiotensin I-converting enzyme (ACE) and breast cancer risk: the multiethnic cohort. Cancer Res. 2003;63:6984–7.PubMed Haiman CA, Henderson SO, Bretsky P, Kolonel LN, Henderson BE. Genetic variation in angiotensin I-converting enzyme (ACE) and breast cancer risk: the multiethnic cohort. Cancer Res. 2003;63:6984–7.PubMed
8.
Zurück zum Zitat Alves Corrêa SA, Ribeiro de Noronha SM, Nogueira-de-Souza NC, Valleta de Carvalho C, Massad Costa AM, Juvenal Linhares J et al. Association between the angiotensin-converting enzyme (insertion/deletion) and angiotensin II type 1 receptor (A1166C) polymorphisms and breast cancer among Brazilian women. J Renin Angiotensin Aldosterone Syst. 2009;10:51–8 Alves Corrêa SA, Ribeiro de Noronha SM, Nogueira-de-Souza NC, Valleta de Carvalho C, Massad Costa AM, Juvenal Linhares J et al. Association between the angiotensin-converting enzyme (insertion/deletion) and angiotensin II type 1 receptor (A1166C) polymorphisms and breast cancer among Brazilian women. J Renin Angiotensin Aldosterone Syst. 2009;10:51–8
9.
Zurück zum Zitat Koh WP, Yuan JM, Sun CL, Van den Berg D, Seow A, Lee HP, et al. Angiotensin I-converting enzyme (ACE) gene polymorphism and breast cancer risk among Chinese women in Singapore. Cancer Res. 2003;63:573–8.PubMed Koh WP, Yuan JM, Sun CL, Van den Berg D, Seow A, Lee HP, et al. Angiotensin I-converting enzyme (ACE) gene polymorphism and breast cancer risk among Chinese women in Singapore. Cancer Res. 2003;63:573–8.PubMed
10.
Zurück zum Zitat González-Zuloeta Ladd AM, Vasquez AA, Sayed-Tabatabaei FA, Coebergh JW, Hofman A, Njajou O, et al. Angiotensin-converting enzyme gene insertion/deletion polymorphism and breast cancer risk. Cancer Epidemiol Biomarkers Prev. 2005;14:2143–6.CrossRefPubMed González-Zuloeta Ladd AM, Vasquez AA, Sayed-Tabatabaei FA, Coebergh JW, Hofman A, Njajou O, et al. Angiotensin-converting enzyme gene insertion/deletion polymorphism and breast cancer risk. Cancer Epidemiol Biomarkers Prev. 2005;14:2143–6.CrossRefPubMed
11.
Zurück zum Zitat Van Der Knaap R, Siemes C, Coebergh JW, Van Duijn CM, Hofman A, Stricker BHC. Renin–angiotensin system inhibitors, angiotensin I-converting enzyme gene insertion/deletion polymorphism, and cancer: The Rotterdam study. Cancer. 2008;112:748–57.CrossRefPubMed Van Der Knaap R, Siemes C, Coebergh JW, Van Duijn CM, Hofman A, Stricker BHC. Renin–angiotensin system inhibitors, angiotensin I-converting enzyme gene insertion/deletion polymorphism, and cancer: The Rotterdam study. Cancer. 2008;112:748–57.CrossRefPubMed
12.
Zurück zum Zitat Oro C, Qian H, Thomas WG. Type 1 angiotensin receptor pharmacology: signaling beyond G proteins. Pharmacol Ther. 2007;113:210–26.CrossRefPubMed Oro C, Qian H, Thomas WG. Type 1 angiotensin receptor pharmacology: signaling beyond G proteins. Pharmacol Ther. 2007;113:210–26.CrossRefPubMed
13.
Zurück zum Zitat Fischer M, Baessler A, Schunkert H. Renin angiotensin system and gender differences in the cardiovascular system. Cardiovasc Res. 2002;53:672–7.CrossRefPubMed Fischer M, Baessler A, Schunkert H. Renin angiotensin system and gender differences in the cardiovascular system. Cardiovasc Res. 2002;53:672–7.CrossRefPubMed
14.
Zurück zum Zitat Wassmann S, Nickenig G. Pathophysiological regulation of the AT1-receptor and implications for vascular disease. J Hypertens. 2006;24:S15–21.CrossRef Wassmann S, Nickenig G. Pathophysiological regulation of the AT1-receptor and implications for vascular disease. J Hypertens. 2006;24:S15–21.CrossRef
15.
Zurück zum Zitat Komukai K, Mochizuki S, Yoshimura M. Gender and the renin–angiotensin–aldosterone system. Fundam Clin Pharmacol. 2010;24:687–98.CrossRefPubMed Komukai K, Mochizuki S, Yoshimura M. Gender and the renin–angiotensin–aldosterone system. Fundam Clin Pharmacol. 2010;24:687–98.CrossRefPubMed
16.
Zurück zum Zitat Afonso N. Women at high risk for breast cancer—what the primary care provider needs to know. J Am Board Fam Med. 2009;22:43–50.CrossRefPubMed Afonso N. Women at high risk for breast cancer—what the primary care provider needs to know. J Am Board Fam Med. 2009;22:43–50.CrossRefPubMed
17.
Zurück zum Zitat Lorincz A, Sukumar S. Molecular links between obesity and breast cancer. Endocr Relat Cancer. 2006;13:279–92.CrossRefPubMed Lorincz A, Sukumar S. Molecular links between obesity and breast cancer. Endocr Relat Cancer. 2006;13:279–92.CrossRefPubMed
18.
Zurück zum Zitat Bianchini F, Kaaks R, Vainio H. Overweight, obesity, and cancer risk. Lancet Oncol. 2002;3:565–74.CrossRefPubMed Bianchini F, Kaaks R, Vainio H. Overweight, obesity, and cancer risk. Lancet Oncol. 2002;3:565–74.CrossRefPubMed
19.
Zurück zum Zitat Namazi S, Monabati A, Ardeshir-Rouhani-Fard S, Azarpira N. Association of angiotensin I converting enzyme (insertion/deletion) and angiotensin II type 1 receptor (A1166C) polymorphisms with breast cancer prognostic factors in iranian population. Mol Carcinog. 2010;49:1022–30.CrossRefPubMed Namazi S, Monabati A, Ardeshir-Rouhani-Fard S, Azarpira N. Association of angiotensin I converting enzyme (insertion/deletion) and angiotensin II type 1 receptor (A1166C) polymorphisms with breast cancer prognostic factors in iranian population. Mol Carcinog. 2010;49:1022–30.CrossRefPubMed
20.
Zurück zum Zitat Koh WP, Yuan JM, Van Den Berg D, Lee HP, Yu MC. Polymorphisms in angiotensin II type 1 receptor and angiotensin I-converting enzyme genes and breast cancer risk among Chinese women in Singapore. Carcinogenesis. 2005;26:459–64.CrossRefPubMed Koh WP, Yuan JM, Van Den Berg D, Lee HP, Yu MC. Polymorphisms in angiotensin II type 1 receptor and angiotensin I-converting enzyme genes and breast cancer risk among Chinese women in Singapore. Carcinogenesis. 2005;26:459–64.CrossRefPubMed
21.
Zurück zum Zitat Li CI, Malone KE, Weiss NS, Boudreau DM, Cushing-Haugen KL, Daling JR. Relation between use of antihypertensive medications and risk of breast carcinoma among women ages 65–79 years. Cancer. 2003;98:1504–13.CrossRefPubMed Li CI, Malone KE, Weiss NS, Boudreau DM, Cushing-Haugen KL, Daling JR. Relation between use of antihypertensive medications and risk of breast carcinoma among women ages 65–79 years. Cancer. 2003;98:1504–13.CrossRefPubMed
22.
Zurück zum Zitat Welsh ML, Buist DSM, Aiello Bowles EJ, Anderson ML, Elmore JG, Li CI. Population-based estimates of the relation between breast cancer risk, tumor subtype, and family history. Breast Cancer Res Treat. 2009;114:549–58.PubMedCentralCrossRefPubMed Welsh ML, Buist DSM, Aiello Bowles EJ, Anderson ML, Elmore JG, Li CI. Population-based estimates of the relation between breast cancer risk, tumor subtype, and family history. Breast Cancer Res Treat. 2009;114:549–58.PubMedCentralCrossRefPubMed
23.
Zurück zum Zitat Dumitrescu RG, Cotarla I. Understanding breast cancer risk—where do we stand in 2005? J Cell Mol Med. 2005;9:208–21.CrossRefPubMed Dumitrescu RG, Cotarla I. Understanding breast cancer risk—where do we stand in 2005? J Cell Mol Med. 2005;9:208–21.CrossRefPubMed
24.
Zurück zum Zitat Pike MC, Spicer DV, Dahmoush L, Press MF. Estrogens, progestogens, normal breast cell proliferation, and breast cancer risk. Epidemiol Rev. 1993;15:17–30.PubMed Pike MC, Spicer DV, Dahmoush L, Press MF. Estrogens, progestogens, normal breast cell proliferation, and breast cancer risk. Epidemiol Rev. 1993;15:17–30.PubMed
25.
Zurück zum Zitat Biller H, Zissel G, Ruprecth B, Nauck M, Busse Grawitz A, Müller-Quernheim J. Genotype-corrected reference values for serum angiotensin-converting enzyme. Eur Respir J. 2006;28:1085–90.CrossRefPubMed Biller H, Zissel G, Ruprecth B, Nauck M, Busse Grawitz A, Müller-Quernheim J. Genotype-corrected reference values for serum angiotensin-converting enzyme. Eur Respir J. 2006;28:1085–90.CrossRefPubMed
26.
Zurück zum Zitat Tiret L, Rigat B, Visvikis S, Breda C, Corvol P, Cambien F, et al. Evidence, from combined segregation and linkage analysis, that a variant of the angiotensin I-converting enzyme (ACE) gene controls plasma ACE levels. Am J Hum Genet. 1992;51:197–205.PubMedCentralPubMed Tiret L, Rigat B, Visvikis S, Breda C, Corvol P, Cambien F, et al. Evidence, from combined segregation and linkage analysis, that a variant of the angiotensin I-converting enzyme (ACE) gene controls plasma ACE levels. Am J Hum Genet. 1992;51:197–205.PubMedCentralPubMed
27.
Zurück zum Zitat Castellon R, Hamdi HK. Demystifying the ACE polymorphism: from genetics to biology. Curr Pharm Des. 2007;13:1191–8.CrossRefPubMed Castellon R, Hamdi HK. Demystifying the ACE polymorphism: from genetics to biology. Curr Pharm Des. 2007;13:1191–8.CrossRefPubMed
28.
Zurück zum Zitat Baudin B. New aspects on angiotensin-converting enzyme: from gene to disease. Clin Chem Lab Med. 2002;40:256–65.CrossRefPubMed Baudin B. New aspects on angiotensin-converting enzyme: from gene to disease. Clin Chem Lab Med. 2002;40:256–65.CrossRefPubMed
29.
Zurück zum Zitat Ceolotto G, Papparella I, Bortoluzzi A, Strapazzon G, Ragazzo F, Bratti P, et al. Interplay between miR-155, AT1R A1166C polymorphism, and AT1R expression in young untreated hypertensives. Am J Hypertens. 2011;24:241–6.CrossRefPubMed Ceolotto G, Papparella I, Bortoluzzi A, Strapazzon G, Ragazzo F, Bratti P, et al. Interplay between miR-155, AT1R A1166C polymorphism, and AT1R expression in young untreated hypertensives. Am J Hypertens. 2011;24:241–6.CrossRefPubMed
30.
Zurück zum Zitat Deshayes F, Nahmias C. Angiotensin receptors: a new role in cancer. Trends Endocrinol Metab. 2005;16:293–9.CrossRefPubMed Deshayes F, Nahmias C. Angiotensin receptors: a new role in cancer. Trends Endocrinol Metab. 2005;16:293–9.CrossRefPubMed
31.
Zurück zum Zitat Rhodes D, Ateeq B, Cao Q, Tomlins S, Mehra R, Laxman B, et al. AGTR1 overexpression defines a subset of breast cancer and confers sensitivity to losartan, an AGTR1 antagonist. Proc Natl Acad Sci U S A. 2009;106:10284–9.PubMedCentralCrossRefPubMed Rhodes D, Ateeq B, Cao Q, Tomlins S, Mehra R, Laxman B, et al. AGTR1 overexpression defines a subset of breast cancer and confers sensitivity to losartan, an AGTR1 antagonist. Proc Natl Acad Sci U S A. 2009;106:10284–9.PubMedCentralCrossRefPubMed
32.
Zurück zum Zitat Tiret L, Bonnardeaux A, Poirier O, Ricard S, Marques-Vidal P, Evans A, et al. Synergistic effects of angiotensin-converting enzyme and angiotensin-II type 1 receptor gene polymorphisms on risk of myocardial infarction. Lancet. 1994;344:910–3.CrossRefPubMed Tiret L, Bonnardeaux A, Poirier O, Ricard S, Marques-Vidal P, Evans A, et al. Synergistic effects of angiotensin-converting enzyme and angiotensin-II type 1 receptor gene polymorphisms on risk of myocardial infarction. Lancet. 1994;344:910–3.CrossRefPubMed
33.
Zurück zum Zitat Fukazawa R, Sonobe T, Hamamoto K, Hamaoka K, Sakata K, Asano T, et al. Possible synergic effect of angiotensin-I converting enzyme gene insertion/deletion polymorphism and angiotensin-II type-1 receptor 1166A/C gene polymorphism on ischemic heart disease in patients with Kawasaki disease. Pediatr Res. 2004;56:597–601.CrossRefPubMed Fukazawa R, Sonobe T, Hamamoto K, Hamaoka K, Sakata K, Asano T, et al. Possible synergic effect of angiotensin-I converting enzyme gene insertion/deletion polymorphism and angiotensin-II type-1 receptor 1166A/C gene polymorphism on ischemic heart disease in patients with Kawasaki disease. Pediatr Res. 2004;56:597–601.CrossRefPubMed
34.
Zurück zum Zitat Szolnoki Z, Maasz A, Magyari L, Horvatovich K, Farago B, Somogyvari F, et al. Coexistence of angiotensin II type-1 receptor A1166C and angiotensin-converting enzyme D/D polymorphism suggests susceptibility for small-vessel-associated ischemic stroke. Neuromolecular Med. 2006;8:353–60.CrossRefPubMed Szolnoki Z, Maasz A, Magyari L, Horvatovich K, Farago B, Somogyvari F, et al. Coexistence of angiotensin II type-1 receptor A1166C and angiotensin-converting enzyme D/D polymorphism suggests susceptibility for small-vessel-associated ischemic stroke. Neuromolecular Med. 2006;8:353–60.CrossRefPubMed
35.
Zurück zum Zitat Álvarez R, Reguero JR, Batalla A, Iglesias-Cubero G, Cortina A, Álvarez V, et al. Angiotensin-converting enzyme and angiotensin II receptor 1 polymorphisms: association with early coronary disease. Cardiovasc Res. 1998;40:375–9.CrossRefPubMed Álvarez R, Reguero JR, Batalla A, Iglesias-Cubero G, Cortina A, Álvarez V, et al. Angiotensin-converting enzyme and angiotensin II receptor 1 polymorphisms: association with early coronary disease. Cardiovasc Res. 1998;40:375–9.CrossRefPubMed
36.
Zurück zum Zitat Burger HG. Physiology and endocrinology of the menopause. Medicine (Baltimore). 2006;34:27–30.CrossRef Burger HG. Physiology and endocrinology of the menopause. Medicine (Baltimore). 2006;34:27–30.CrossRef
37.
Zurück zum Zitat Dean SA, Tan J, O'Brien ER, Leenen FHH. 17β-Estradiol downregulates tissue angiotensin-converting enzyme and ANG II type 1 receptor in female rats. Am J Physiol Regul Integr Comp Physiol. 2005;288:R759–66.CrossRefPubMed Dean SA, Tan J, O'Brien ER, Leenen FHH. 17β-Estradiol downregulates tissue angiotensin-converting enzyme and ANG II type 1 receptor in female rats. Am J Physiol Regul Integr Comp Physiol. 2005;288:R759–66.CrossRefPubMed
38.
Zurück zum Zitat Dubey RK, Oparil S, Imthurn B, Jackson EK. Sex hormones and hypertension. Cardiovasc Res. 2002;53:688–708.CrossRefPubMed Dubey RK, Oparil S, Imthurn B, Jackson EK. Sex hormones and hypertension. Cardiovasc Res. 2002;53:688–708.CrossRefPubMed
Metadaten
Titel
Lack of association of genetic polymorphisms of angiotensin converting enzyme 1 and angiotensin II type 1 receptor with breast cancer risk in Iranian population
verfasst von
Soha Namazi
Ahmad Monabati
Shirin Ardeshir-Rouhani-Fard
Negar Azarpira
Publikationsdatum
01.10.2013
Verlag
Springer Netherlands
Erschienen in
Tumor Biology / Ausgabe 5/2013
Print ISSN: 1010-4283
Elektronische ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-013-0852-6

Weitere Artikel der Ausgabe 5/2013

Tumor Biology 5/2013 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.